The FDA wants to pull its 7 October 2021 approval of Tavneos, ChemoCentryx’s drug for a rare autoimmune vasculitis, saying the pivotal trial relied on manipulated data despite only modest remission gains and a narrowly favorable advisory vote. Amgen acquired ChemoCentryx about a year after approval,